PL3229843T3 - Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji - Google Patents

Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji

Info

Publication number
PL3229843T3
PL3229843T3 PL15801384T PL15801384T PL3229843T3 PL 3229843 T3 PL3229843 T3 PL 3229843T3 PL 15801384 T PL15801384 T PL 15801384T PL 15801384 T PL15801384 T PL 15801384T PL 3229843 T3 PL3229843 T3 PL 3229843T3
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL15801384T
Other languages
English (en)
Inventor
Marie-Edith MEYRE
Agnès Pottier
Matthieu Germain
Céline BERJAUD
Audrey DARMON
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of PL3229843T3 publication Critical patent/PL3229843T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL15801384T 2014-11-25 2015-11-24 Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji PL3229843T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306871 2014-11-25
PCT/EP2015/077423 WO2016083331A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof
EP15801384.7A EP3229843B1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
PL3229843T3 true PL3229843T3 (pl) 2020-06-29

Family

ID=52013979

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15801384T PL3229843T3 (pl) 2014-11-25 2015-11-24 Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji

Country Status (11)

Country Link
US (2) US20170258937A1 (pl)
EP (1) EP3229843B1 (pl)
JP (1) JP6722688B2 (pl)
AR (1) AR102778A1 (pl)
DK (1) DK3229843T3 (pl)
ES (1) ES2774365T3 (pl)
LT (1) LT3229843T (pl)
PL (1) PL3229843T3 (pl)
PT (1) PT3229843T (pl)
TW (1) TW201628644A (pl)
WO (1) WO2016083331A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスNanobiotix 治療用ワクチンとしての使用のためのナノ粒子
AU2021389027A1 (en) * 2020-11-30 2023-06-29 Anbition S.R.L. Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2930421B2 (ja) * 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
SG145712A1 (en) * 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
CA3051495A1 (en) * 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
WO2012051220A1 (en) * 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
EP2670393B8 (en) 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
IN2014MN02089A (pl) * 2012-03-20 2015-09-11 Einstein Coll Med
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
MA38687A1 (fr) * 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
WO2016083336A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof

Also Published As

Publication number Publication date
LT3229843T (lt) 2020-05-25
AR102778A1 (es) 2017-03-22
DK3229843T3 (da) 2020-03-09
JP6722688B2 (ja) 2020-07-15
WO2016083331A1 (en) 2016-06-02
EP3229843B1 (en) 2020-01-01
EP3229843A1 (en) 2017-10-18
US20180339062A1 (en) 2018-11-29
PT3229843T (pt) 2020-03-06
ES2774365T3 (es) 2020-07-20
TW201628644A (zh) 2016-08-16
US11191846B2 (en) 2021-12-07
US20170258937A1 (en) 2017-09-14
JP2017538782A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
PL4036094T3 (pl) Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie
GB201409471D0 (en) Pharmaceutical composition
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
HUE056175T2 (hu) Gyógyászati készítmények, elõállításuk és alkalmazásaik
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
PT3229843T (pt) Composição farmacêutica, a sua preparação e as suas utilizações
ZA201703398B (en) Pharmaceutical composition and methods
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL249073A0 (en) Cytin-glucan complex, its preparation and uses
PT3089740T (pt) Composição farmacêutica
SG10201504332VA (en) Pharmaceutical Composition
GB2509426B (en) Clomazone composition, its preparation and use thereof
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน